Breast cancer: gene signature is similarly prognostic in ILC and IDC


  • Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The MammaPrint 70-gene signature has a similar prognostic performance in women with early-stage invasive lobular carcinoma (ILC) or with invasive ductal carcinoma (IDC).
  • The findings were presented at the 12th European Breast Cancer Conference.

Why this matters

  • Chemotherapy decisions for patients with ILC remain controversial.

Study design

  • Exploratory analysis of phase 3 MINDACT trial.
  • Data from 5313 women who underwent surgery for early-stage breast cancer (node-negative or up to 3 positive lymph nodes) and who were risk-stratified to receive or skip adjuvant chemotherapy on the basis of both clinical risk and the MammaPrint score for genomic risk.
  • Funding: Breast Cancer Research Foundation.

Key results

  • Median follow-up was 8.7 years.
  • MammaPrint classified 39% of the IDC group and 16% of the ILC group (10% of those with classic disease and 23% of those with variant disease) as genomically high risk for recurrence.
  • 5-year rate of distant metastasis-free survival among all patients classified as genomic high risk was 92.3% (95% CI, 90.9%-93.5%) in women with IDC and 89.4% (95% CI, 78.5%-94.9%) in women with ILC.

Limitations

  • Exploratory analysis.